Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MYC | P01106 | 3/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9925938 | 0.80 | AOC3 (0.35) | GBA1AOC3HCAR3 | |
| SCHEMBL830188 | 0.80 | NOS3 (0.33) | GBA1 | |
| SCHEMBL9925945 | 0.79 | CKS1B (0.34) | GBA1HCAR3 | |
| SCHEMBL9924584 | 0.77 | GBA1 (0.48) | GBA1SMN1; SMN2L3MBTL1KMT2AAOC3 | |
| SCHEMBL14649104 | 0.76 | GBA1 (0.47) | GBA1SMN1; SMN2L3MBTL1KMT2AAOC3 | |
| SCHEMBL18708818 | 0.76 | GBA1 (0.47) | GBA1SMN1; SMN2L3MBTL1KMT2AAOC3 | |
| SCHEMBL16646632 | 0.75 | HCAR3 (0.44) | AOC3ALDH1A1HCAR3 | |
| SCHEMBL19420653 | 0.74 | GBA1 (0.31) | GBA1 | |
| SCHEMBL9924594 | 0.72 | GBA1 (0.44) | GBA1SMN1; SMN2L3MBTL1KMT2AAOC3 | |
| SCHEMBL179535 | 0.72 | GBA1 (0.44) | GBA1SMN1; SMN2L3MBTL1KMT2AAOC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170281614-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE LLC | 2017-10-05 | — | — | US | disclosed |
| US-20170137407-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS, INC. | 2017-05-18 | — | — | US | disclosed |
| US-20120149701-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE, INC. | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170137407-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | AKT3, PIK3CA, AKT1 | GBA1 671/4885SMN1; SMN2 1326/4885L3MBTL1 2904/4885 |
| US-20120149701-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | PIK3CA, AKT3, PIK3C2A | GBA1 856/4885SMN1; SMN2 2859/4885L3MBTL1 2802/4885 |
| US-20170281614-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | PIK3CA, PIK3CG, PIK3CB | GBA1 1016/4885SMN1; SMN2 3325/4885L3MBTL1 4132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.